Protalix BioTherapeutics, Inc. — Form 10-Q
Filed August 12, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Dror Bashan (CEO) and Gilad Mamlok (CFO) certified the Form 10-Q for the period ended June 30, 2026, filed August 12, 2026. Both officers certified that the report contains no untrue material statements, that financial statements fairly present the company's condition, and that disclosure controls and internal controls over financial reporting are effective. No material weaknesses, deficiencies, or fraud were disclosed.
Why this rating
Routine Section 302/906 certifications; standard quarterly filing requirement. No disclosed control weaknesses or anomalies. Administrative compliance, not operational event.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.